肝内胆管癌外科治疗与生存分析
回顾性分析704例接受肝切除术的肝内胆管癌患者,中位总生存27.1个月,5年生存率34.1%。淋巴结转移患者需区域淋巴结清扫,术后辅助治疗可降低复发并延长生存。
要点
- 手术仍是肝内胆管癌获得长期生存的重要手段。
- 合并淋巴结转移者需行区域淋巴结清扫。
- 术后辅助治疗可降低复发率并延长总生存。
核心结论
- 手术是肝内胆管癌患者获得长期生存的重要手段,合并淋巴结转移者需行区域淋巴结清扫,术后辅助治疗可降低复发率并延长生存时间。
研究设计与样本
- 基于肝胆肿瘤专病数据库的回顾性研究,连续纳入2009年5月至2022年12月南京医科大学第一附属医院肝胆中心704例初诊肝内胆管癌并接受肝切除术患者,男380例、女324例,年龄61(15)岁(范围27~88岁)。
主要发现
- 704例患者中,349例(49.6%)接受大范围肝切除(≥3段),331例(47.0%)行术中淋巴结清扫,524例(74.4%)达到R0切除。
- Clavien-DindoⅢ级及以上并发症发生率为16.5%(116/704),30 d内病死率为3.0%(21/704)。
- 中位总生存时间27.1个月,1、3、5、10年总生存率分别为69.1%、42.4%、34.1%、24.5%;中位无复发生存时间10.5个月,1、3、5、10年无复发生存率分别为46.0%、25.4%、21.9%、16.9%。
- 按第8版AJCC分期,ⅠA、ⅠB、Ⅱ、ⅢA、ⅢB、Ⅳ期5年总生存率分别为68.4%、43.2%、30.3%、32.2%、14.0%、0,5年无复发生存率分别为55.8%、28.1%、13.8%、21.2%、3.3%、0。
- 2019—2022年收治患者总生存优于2009—2013年及2014—2018年(P值均<0.01);调整预后因素后,2019—2022年手术患者术后辅助治疗组无复发生存和总生存优于无辅助治疗组(P值均<0.01)。
关键数值与推荐
- ⅠB期与Ⅱ期、ⅠB期与ⅢA期、Ⅱ期与ⅢA期相比,总生存和无复发生存差异均无统计学意义(Log-rank检验:P值均>0.05)。
- 未清扫组、活检且N0亚组与清扫且N0亚组间无复发生存和总生存差异均无统计学意义(P值均>0.05)。
- 活检且N1亚组和清扫且N1亚组无复发生存和总生存均差于清扫且N0亚组(P值均<0.05),清扫且N1亚组总生存优于活检且N1亚组(P=0.017)。
临床怎么用
- 对肝内胆管癌患者应积极行肝切除术以达到R0切除,合并淋巴结转移者需行区域淋巴结清扫。
- 术后辅助治疗可用于降低肿瘤复发率并延长总生存,尤其适用于近年手术患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the survival benefit of surgical treatment for intrahepatic cholangiocarcinoma. Methods: This study is conducted based on the hepatobiliary tumor registry database. From May 2009 to December 2022,a total of 704 patients who were initially diagnosed with intrahepatic cholangiocarcinoma and underwent liver resection were consecutively enrolled at the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University. Among them,there were 380 males and 324 females,aged (M(IQR)) 61(15) years(range:27 to 88 years). Twenty-six (3.7%) patients received neoadjuvant therapy before surgery. The overall survival(OS) and disease-free survival(DFS) rates were estimated by life table method, and Kaplan-Meier survival curves were plotted. Log-rank test was used to compare the survival difference among tumor-node-metastasis(TNM) staging or three periods. The OS and DFS differences among lymph node groups or adjuvant treatment groups were quantified as HR with 95% CI estimated using Cox proportional-hazards model with adjustment for prognostic factors. Results: Among the 704 patients,349 cases(49.6%) underwent major hepatectomy (≥3 segments),331(47.0%) had lymph node resection during surgery,and 524 cases(74.4%) achieved R0 resection. The morbidity of Clavien-Dindo grade Ⅲ or higher complications was 16.5%(116/704),with a mortality rate of 3.0%(21/704) within 30 days post-surgery. The median OS time was 27.1 months, and the OS rates at 1-,3-,5- and 10-year were 69.1%, 42.4%,34.1% and 24.5%,respectively. The median DFS time was 10.5 months,and the corresponding DFS rates were 46.0%,25.4%,21.9% and 16.9%,respectively. According to the 8th edition of AJCC staging system, the 5-year survival rates for ⅠA,ⅠB,Ⅱ,ⅢA,ⅢB and Ⅳ were 68.4%, 43.2%, 30.3%,32.2%,14.0% and 0,respectively. The corresponding DFS rates were 55.8%, 28.1%,13.8%,21.2%,3.3% and 0,respectively. There were no statistically significant differences of OS or DFS between stage ⅠB and Ⅱ, stage ⅠB and ⅢA, or between stage Ⅱ and ⅢA(Log-rank test:all P>0.05),while there were significant differences of OS and DFS among other stages(Log-rank test:all P<0.05). Using Cox model with adjustment for prognostic factors, there were no statistically significant differences of OS and DFS between non-lymphadenectomy group or the biopsy-N0 group and dissection-N0 group(both P>0.05). However,the overall and disease-free survival of the biopsy-N1 group or dissection-N1 group were worse than those of dissection-N0 group(both P<0.05),with overall survival being better in dissection-N1 group than biopsy-N1 group(P=0.017). Overall survival in the period from 2019 to 2022 were significantly superior to that during the periods from 2009 to 2013 and 2014 to 2018(both P<0.01). Adjusting for prognostic factors, the disease-free and overall survival of the postoperative adjuvant therapy group were significantly better than those of the observation group in the period 2019 to 2022(both P<0.01). Conclusions: Surgery remains a milestone for achieving long-term survival for patients with intrahepatic cholangiocarcinoma. Regional lymph node dissection is required for patients with lymph node metastasis. Adjuvant therapy can significantly reduce tumor recurrence and prolong overall survival. 目的: 探讨肝内胆管癌的外科治疗效果和预后。 方法: 本研究基于肝胆肿瘤专病数据库开展。回顾性收集2009年5月至2022年12月南京医科大学第一附属医院肝胆中心连续收治的704例初诊为肝内胆管癌并接受肝切除术的患者资料,男性380例,女性324例,年龄[M(IQR)]61(15)岁(范围:27~88岁)。26例(3.7%)患者术前接受了新辅助治疗。采用寿命表法估计各时间点患者的生存率,绘制Kaplan-Meier生存曲线,采用Log-rank检验比较不同肿瘤分期、不同手术时期患者的生存差异,采用Cox比例风险模型调整预后因素后比较不同淋巴结分组、有无辅助治疗患者的生存差异。 结果: 704例患者中,349例(49.6%)接受大范围肝切除(≥3段),331例(47.0%)行术中淋巴结清扫,524例(74.4%)达到R0切除。Clavien-Dindo并发症分级系统Ⅲ级及以上并发症发生率为16.5%(116/704),30 d内病死率为3.0%(21/704)。704例患者的中位生存时间为27.1个月,1、3、5、10年总体生存率分别为69.1%、42.4%、34.1%、24.5%;中位无复发生存时间为10.5个月,1、3、5、10年无复发生存率分别为46.0%、25.4%、21.9%、16.9%。按照第8版AJCC分期系统,ⅠA期、ⅠB期、Ⅱ期、ⅢA期、ⅢB期、Ⅳ期患者的5年总体生存率分别为68.4%、43.2%、30.3%、32.2%、14.0%、0,5年无复发生存率分别为55.8%、28.1%、13.8%、21.2%、3.3%、0;ⅠB期与Ⅱ期、ⅠB期与ⅢA期、Ⅱ期与ⅢA期相比,总体生存和无复发生存的差异均无统计学意义(Log-rank检验:P值均>0.05),其他分期两两比较总体生存和无复发生存的差异均有统计学意义(Log-rank检验:P值均<0.05)。采用多因素Cox回归调整预后因素后,未清扫组、活检且N0亚组与清扫且N0亚组之间的无复发生存和总体生存的差异均无统计学意义(P值均>0.05),活检且N1亚组和清扫且N1亚组的无复发生存和总体生存均差于清扫且N0亚组(P值均<0.05),而清扫且N1亚组的总体生存优于活检且N1亚组(P=0.017)。2019—2022年收治患者的总体生存优于2009—2013年、2014—2018年收治患者(P值均<0.01);调整预后因素后,2019—2022年手术患者术后辅助治疗组的无复发生存和总体生存优于无辅助治疗组(P值均<0.01)。 结论: 手术仍然是肝内胆管癌患者获得长期生存的重要手段,合并淋巴结转移的患者需要行区域淋巴结清扫。术后辅助治疗可降低肿瘤复发率,延长患者生存时间。.
引用
- Zhang H, Jiao CY, Li CX, et al. [Surgical treatment and survival analyses of intrahepatic cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40058785. doi:10.3760/cma.j.cn112139-20240927-00443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。